Skip Navigation


Carcinogenesis Advance Access originally published online on July 20, 2009
Carcinogenesis 2009 30(10):1722-1728; doi:10.1093/carcin/bgp177
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/10/1722    most recent
bgp177v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Srinivasan, M.
Right arrow Articles by C.Ragin, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Srinivasan, M.
Right arrow Articles by C.Ragin, C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Human papillomavirus type 16 and 18 in primary lung cancers—a meta-analysis

Malini Srinivasan1,2, Emanuela Taioli3 and Camille C.Ragin3,*

1 Department of Epidemiology, Graduate School of Public Health
2 Division of Cancer Prevention and Population Science, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
3 Department of Epidemiology and Biostatistics, State University of New York Downstate Medical Center, 450 Clarkson Avenue, Box 43, Brooklyn, NY 11203, USA

* To whom correspondence should be addressed. Tel: +1 718 221 5280; Fax: +1 718 270 2533; Email: camille.ragin{at}downstate.edu

Lung cancer is the leading cause of cancer mortality worldwide. A possible carcinogenic role of human papillomavirus (HPV) has been investigated for >20 years and has major clinical and public health implications. We performed a meta-analysis to assess the prevalence of HPV16 and HPV18 in primary lung cancers (2435 subjects from 37 published studies). The overall HPV prevalence ranged from 0.0 to 78.3% with large heterogeneity across geographic regions and histological tissue types. A higher proportion, 50% (7/14), of the European studies reported low or no HPV prevalence (0–10%) compared with the Asian studies, 22% (4/18). When the analysis was limited to HPV16 and HPV18 prevalence, a higher prevalence in Asia (HPV16 = 11.6% and HPV18 = 8.8%) than in Europe (HPV16 = 3.5% and HPV18 = 3.6%) was observed. Studies using HPV-specific primers resulted in higher prevalence rates than consensus HPV primers (HPV16: Asia = 13% and Europe = 6%; HPV18: Asia = 13% and Europe = 5%). Further studies are needed to elucidate the role of HPV in lung carcinogenesis with careful thought given to study design and laboratory detection methods for a more accurate assessment of HPV status in lung tumors.

Abbreviations: BAC, bronchioloalveolar carcinoma; CI, confidence interval; HPV, human papillomavirus; PCR, polymerase chain reaction

Received May 22, 2009; revised July 11, 2009; accepted July 13, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.